Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD) -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (385)	1/16/2007 3:46:29 PM
From: tuck	Respond to of 588

Digging around some more, I find a study that seems to contradict the recent Natesan et. al. study that I pointed to on at least one front. Natesan et. al. found little Fos induction in the nucleus accumbens, but these guys found noticeable Fos induction there: nature.com So who's right? How important is that parameter is in predicting efficacy? As for the agranulocytosis issue . . . Harry has probably seen these, but for the rest of us . . . in reference to the studies cited in the Lehman note posted by George, here's a couple of related full text freebies. The ones actually cited in the Lehman note are abstracts only unless you pay. molpharm.aspetjournals.org molpharm.aspetjournals.org Cheers, Tuck